Related Experiment Video
Updated: Mar 8, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Heat shock transcription factor 1 protects against pressure overload-induced cardiac fibrosis via Smad3
Ning Zhou1, Yong Ye2, Xingxu Wang2
1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.
Insights
Heat shock transcription factor 1 (HSF1) protects against cardiac fibrosis by inhibiting Smad3 activation. HSF1 deficiency worsens fibrosis and heart dysfunction, highlighting its therapeutic potential in fibrotic heart disease.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Fibrosis Research
Background:
- Cardiac fibrosis, characterized by stiffening and reduced compliance, is a major risk factor for heart failure.
- Heat shock transcription factor 1 (HSF1) is an intrinsic cardioprotective factor, but its role in cardiac fibrosis is not fully understood.
Purpose of the Study:
- To investigate the role of HSF1 in pressure overload-induced cardiac fibrosis.
- To elucidate the underlying molecular mechanisms by which HSF1 regulates cardiac fibrosis.
Main Methods:
- Utilized a mouse model of transverse aortic constriction (TAC) to induce pressure overload.
- Employed HSF1 transgenic (TG) and knockout (KO) mice, alongside wild-type littermates.
- Investigated HSF1 and Smad3 phosphorylation and nuclear distribution in cardiac tissue and fibroblasts.
- Assessed cardiac fibrosis and dysfunction through histological and functional analyses.
Main Results:
- HSF1 phosphorylation was downregulated in TAC-induced fibrotic hearts and mechanically stressed cardiac fibroblasts.
- HSF1 overexpression attenuated TAC-induced cardiac fibrosis and dysfunction, while HSF1 deficiency exacerbated these conditions.
- HSF1 inhibited the phosphorylation and nuclear translocation of Smad3, a key fibrotic mediator.
- Direct binding between phosphorylated HSF1 and Smad3 was observed, which was disrupted by mechanical stress.
Conclusions:
- HSF1 acts as a novel negative regulator of cardiac fibrosis.
- HSF1 mitigates cardiac fibrosis by directly inhibiting Smad3 activation.
- Modulating HSF1 activity may represent a therapeutic strategy for treating fibrotic heart disease.
Abstract:
Fibrotic cardiac muscle exhibits high stiffness and low compliance which are major risk factors of heart failure. Although heat shock transcription factor 1 (HSF1) was identified as an intrinsic cardioprotective factor, the role that HSF1 plays in cardiac fibrosis remains unclear. Our study aims to investigate the role of HSF1 in pressure overload-induced cardiac fibrosis and the underlying mechanism. HSF1 phosphorylation was significantly downregulated in transverse aortic constriction (TAC)-treated mouse hearts and mechanically stretched cardiac fibroblasts (cFBs). HSF1 transgenic (TG) mice, HSF1 deficient heterozygote (KO) mice, and their wild-type littermates were subjected to sham or TAC surgery for 4 weeks. HSF1 overexpression significantly attenuated pressure overload-induced cardiac fibrosis and dysfunction. Conversely, HSF1 KO mice showed deteriorated fibrotic response and cardiac dysfunction upon TAC. Moreover, we uncovered that overexpression of HSF1 protected against fibrotic response of cFBs to pressure overload. Mechanistically, we observed that the phosphorylation and the nuclear distribution of the Smad family member 3 (Smad3) were significantly decreased in HSF1-overexpressing mouse hearts, while being greatly increased in HSF1 KO mouse hearts upon TAC, compared to the control hearts, respectively. Similar alteration of Smad3 phosphorylation and nuclear distribution were found in isolated mouse cardiac fibroblasts and mechanically stretched cFBs. Constitutively active Smad3 blocked the anti-fibrotic effect of HSF1 in cFBs. Furthermore, we found a direct binding of phosphorylated HSF1 and Smad3, which can be suppressed by mechanical stress. In conclusion, the present study demonstrated for the first time that HSF1 acts as a novel negative regulator of cardiac fibrosis by blocking Smad3 activation.
Key Messages:
HSF1 activity is decreased in fibrotic hearts. HSF1 overexpression attenuates pressure overload-induced cardiac fibrosis and dysfunction. Deficiency of HSF1 deteriorates fibrotic response and cardiac dysfunction upon TAC. HSF1 inhibits phosphorylation and nuclear distribution of Smad3 via direct binding to Smad3. Active Smad3 blocks the anti-fibrotic effect of HSF1.
Related Concept Videos
TGF - β Signaling Pathway
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pathophysiology of Heart Failure

